FierceBiotechOriginal article
{"a":[{"_":"Electra aims for $342M IPO to power inflammatory drug’s push through phase 3","$":{"href":"/biotech/electra-aims-342m-ipo-power-inflammatory-drugs-push-through-phase-3","hreflang":"en"}}]}
IPO/OfferingipsoprubartPositive
AI Analysis
Summary
Electra Therapeutics is pursuing an IPO to raise up to $341.9 million to fund the Phase 3 clinical development of ipsoprubart, its inflammatory disorder drug.
Clinical Trial Data
Phase
3
Importance:7/10
Sentiment:
0.40
IPOcapital_raiseclinical_developmentinflammatory_disorder
Related Companies
Read the original article
Published by FierceBiotech on September 14, 2026 8:55 AM